Global artificial pancreas device system (APDS) Market Size, by Technology (Threshold Suspended Device Systems, Treat to Range/Control to Range (TTR/CTR), and Treat to Target/ Control to Target (TTR/CTT)), by Distribution Channel (Hospitals & Clinics, Online Channels, and Retail Channels), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 123.5 Mn in 2018, and is expected to exhibit a CAGR of 14.1% over the forecast period (2020–2027), as highlighted in a new report published by Coherent Market Insights.
In November 2018, Diabeloop SA, a France- based medical device company, received the CE marking for its new artificial pancreas system DBLG1 for adults with type 1 diabetes.
Approval and launch of such novel artificial pancreas device systems (APDS) is expected to drive growth of the APDS market over the forecast period.
Browse 25 Market Data Tables and 28 Figures spread through 150 Pages and in-depth TOC on Global Artificial Pancreas Device System (APDS) Market Technology (Threshold Suspended Device Systems, Treat to Range/Control to Range (TTR/CTR), and Treat to Target/ Control to Target (TTR/CTT)), by Distribution Channel (Hospitals & Clinics, Online Channels, and Retail Channels), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2027
To know the latest trends and insights prevalent in the global Artificial Pancreas Device System (APDS) market, click the link below:
Key players in the market are focusing on strategic partnerships and collaborations for developing novel artificial pancreas device systems. Such partnerships among key players might lead to development of novel devices, and drive the global artificial pancreas device system (APDS) market growth over the forecast period.
For instance, in April 2019, Diabeloop SA and ViCentra entered a distribution agreement to make the DBLG1 artificial pancreas system commercially available in selected countries in Europe.
In 2015, Medtronic Plc., and Israel- based company, DreaMed Diabetes entered an agreement which incorporated DreaMed’s patented artificial pancreas technology into Medtronic’s insulin pumps. According to the agreement, DreaMed received undisclosed royalties for Medtronic devices that utilize the flagship GlucoSitter automated insulin delivery system.
Key Takeaways of the Global Artificial Pancreas Device System (APDS) Market:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.